[1]
|
Simon, R.A., Barazanji, N., Jones, M.P., Bednarska, O., Icenhour, A., Engström, M., et al. (2021) Vasoactive Intestinal Polypeptide Plasma Levels Associated with Affective Symptoms and Brain Structure and Function in Healthy Females. Scientific Reports, 11, Article No. 1406. https://doi.org/10.1038/s41598-020-80873-2
|
[2]
|
Myers-Joseph, D., Wilmes, K.A., Fernandez-Otero, M., Clopath, C. and Khan, A.G. (2024) Disinhibition by VIP Interneurons Is Orthogonal to Cross-Modal Attentional Modulation in Primary Visual Cortex. Neuron, 112, 628-645.E7. https://doi.org/10.1016/j.neuron.2023.11.006
|
[3]
|
Paran, D., Elkayam, O., Mayo, A., et al. (2001) A Pilot Study of a Long Acting Somatostatin Analogue for the Treatment of Refractory Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 60, 888-891.
|
[4]
|
Gonzalez-Rey, E., Varela, N., Sheibanie, A.F., Chorny, A., Ganea, D. and Delgado, M. (2006) Cortistatin, an Antiinflammatory Peptide with Therapeutic Action in Inflammatory Bowel Disease. Proceedings of the National Academy of Sciences of the United States of America, 103, 4228-4233. https://doi.org/10.1073/pnas.0508997103
|
[5]
|
Chandrasekharan, B., Nezami, B.G. and Srinivasan, S. (2013) Emerging Neuropeptide Targets in Inflammation: NPY and VIP. American Journal of Physiology-Gastrointestinal and Liver Physiology, 304, G949-G957. https://doi.org/10.1152/ajpgi.00493.2012
|
[6]
|
Huang, J., Fu, X., Chen, X., Li, Z., Huang, Y. and Liang, C. (2021) Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis. Frontiers in Immunology, 12, Article 686155. https://doi.org/10.3389/fimmu.2021.686155
|
[7]
|
Brown, P., Pratt, A.G. and Hyrich, K.L. (2024) Therapeutic Advances in Rheumatoid Arthritis. BMJ, 384, e070856. https://doi.org/10.1136/bmj-2022-070856
|
[8]
|
Martínez, C., Ortiz, A.M., Juarranz, Y., Lamana, A., Seoane, I.V., Leceta, J., et al. (2014) Serum Levels of Vasoactive Intestinal Peptide as a Prognostic Marker in Early Arthritis. PLOS ONE, 9, e85248. https://doi.org/10.1371/journal.pone.0085248
|
[9]
|
Šteigerová, M., Šíma, M. and Slanař, O. (2023) Pathogenesis of Collagen-Induced Arthritis: Role of Immune Cells with Associated Cytokines and Antibodies, Comparison with Rheumatoid Arthritis. Folia Biologica, 69, 41-49. https://doi.org/10.14712/fb2023069020041
|
[10]
|
Delgado, M., Abad, C., Martinez, C., Leceta, J. and Gomariz, R.P. (2001) Vasoactive Intestinal Peptide Prevents Experimental Arthritis by Downregulating Both Autoimmune and Inflammatory Components of the Disease. Nature Medicine, 7, 563-568. https://doi.org/10.1038/87887
|
[11]
|
Juarranz, Y., Abad, C., Martinez, C., et al. (2005) Protective Effect of Vasoactive Intestinal Peptide on Bone Destruction in the Collagen-Induced Arthritis Model of Rheumatoid Arthritis. Arthritis Research & Therapy, 7, R1034-R1045.
|
[12]
|
Juarranz, M.G. (2004) Vasoactive Intestinal Peptide Modulates Proinflammatory Mediator Synthesis in Osteoarthritic and Rheumatoid Synovial Cells. Rheumatology, 43, 416-422. https://doi.org/10.1093/rheumatology/keh061
|
[13]
|
Gutiérrez-Cañas, I., Juarranz, Y., Santiago, B., Martínez, C., Gomariz, R.P., Pablos, J.L., et al. (2008) Immunoregulatory Properties of Vasoactive Intestinal Peptide in Human T Cell Subsets: Implications for Rheumatoid Arthritis. Brain, Behavior, and Immunity, 22, 312-317. https://doi.org/10.1016/j.bbi.2007.09.007
|
[14]
|
Carrión, M., Pérez-García, S., Martínez, C., Juarranz, Y., Estrada-Capetillo, L., Puig-Kröger, A., et al. (2016) VIP Impairs Acquisition of the Macrophage Proinflammatory Polarization Profile. Journal of Leukocyte Biology, 100, 1385-1393. https://doi.org/10.1189/jlb.3a0116-032rr
|
[15]
|
Muschter, D., Schäfer, N., Stangl, H., Straub, R.H. and Grässel, S. (2015) Sympathetic Neurotransmitters Modulate Osteoclastogenesis and Osteoclast Activity in the Context of Collagen-Induced Arthritis. PLOS ONE, 10, e0139726. https://doi.org/10.1371/journal.pone.0139726
|
[16]
|
Gilliland, A., Chan, J.J., De Wolfe, T.J., Yang, H. and Vallance, B.A. (2024) Pathobionts in Inflammatory Bowel Disease: Origins, Underlying Mechanisms, and Implications for Clinical Care. Gastroenterology, 166, 44-58. https://doi.org/10.1053/j.gastro.2023.09.019
|
[17]
|
Kubota, Y., Petras, R.E., Ottaway, C.A., Tubbs, R.R., Farmer, R.G. and Fiocchi, C. (1992) Colonic Vasoactive Intestinal Peptide Nerves in Inflammatory Bowel Disease. Gastroenterology, 102, 1242-1251. https://doi.org/10.1016/0016-5085(92)90762-n
|
[18]
|
Sun, X., Guo, C., Zhao, F., Zhu, J., Xu, Y., Liu, Z., et al. (2019) Vasoactive Intestinal Peptide Stabilizes Intestinal Immune Homeostasis through Maintaining Interleukin-10 Expression in Regulatory B Cells. Theranostics, 9, 2800-2811. https://doi.org/10.7150/thno.34414
|
[19]
|
Wu, X., Conlin, V.S., Morampudi, V., Ryz, N.R., Nasser, Y., Bhinder, G., et al. (2015) Vasoactive Intestinal Polypeptide Promotes Intestinal Barrier Homeostasis and Protection against Colitis in Mice. PLOS ONE, 10, e0125225. https://doi.org/10.1371/journal.pone.0125225
|
[20]
|
Abad, C., Martinez, C., Juarranz, M.G., Arranz, A., Leceta, J., Delgado, M., et al. (2003) Therapeutic Effects of Vasoactive Intestinal Peptide in the Trinitrobenzene Sulfonic Acid Mice Model of Crohn’s Disease. Gastroenterology, 124, 961-971. https://doi.org/10.1053/gast.2003.50141
|
[21]
|
Conlin, V.S., Wu, X., Nguyen, C., Dai, C., Vallance, B.A., Buchan, A.M.J., et al. (2009) Vasoactive Intestinal Peptide Ameliorates Intestinal Barrier Disruption Associated with Citrobacter rodentium-Induced Colitis. American Journal of Physiology-Gastrointestinal and Liver Physiology, 297, G735-G750. https://doi.org/10.1152/ajpgi.90551.2008
|
[22]
|
Villanueva-Romero, R., Gutiérrez-Cañas, I., Carrión, M., Pérez-García, S., Seoane, I.V., Martínez, C., et al. (2018) The Anti-Inflammatory Mediator, Vasoactive Intestinal Peptide, Modulates the Differentiation and Function of Th Subsets in Rheumatoid Arthritis. Journal of Immunology Research, 2018, Article ID: 6043710. https://doi.org/10.1155/2018/6043710
|
[23]
|
Beydon, M., McCoy, S., Nguyen, Y., Sumida, T., Mariette, X. and Seror, R. (2023) Epidemiology of Sjögren syndrome. Nature Reviews Rheumatology, 20, 158-169. https://doi.org/10.1038/s41584-023-01057-6
|
[24]
|
Törnwall, J., Uusitalo, H., Hukkanen, M., et al. (1994) Distribution of Vasoactive Intestinal Peptide (VIP) and Its Binding Sites in Labial Salivary Glands in Sjögren’s Syndrome and in Normal Controls. Clinical and Experimental Rheumatology, 12, 287-292.
|
[25]
|
Cha, S., Peck, A.B. and Humphreys-Beher, M.G. (2002) Progress in Understanding Autoimmune Exocrinopathy Using The Non-Obese Diabetic Mouse: An Update. Critical Reviews in Oral Biology & Medicine, 13, 5-16. https://doi.org/10.1177/154411130201300103
|
[26]
|
Groneberg, D.A., Springer, J. and Fischer, A. (2001) Vasoactive Intestinal Polypeptide as Mediator of Asthma. Pulmonary Pharmacology & Therapeutics, 14, 391-401. https://doi.org/10.1006/pupt.2001.0306
|
[27]
|
Li, C., Zhu, F., Wu, B. and Wang, Y. (2017) Vasoactive Intestinal Peptide Protects Salivary Glands against Structural Injury and Secretory Dysfunction via IL-17A and AQP5 Regulation in a Model of Sjögren Syndrome. Neuroimmunomodulation, 24, 300-309. https://doi.org/10.1159/000486859
|
[28]
|
Lodde, B.M. (2006) Effect of Human Vasoactive Intestinal Peptide Gene Transfer in a Murine Model of Sjogren’s Syndrome. Annals of the Rheumatic Diseases, 65, 195-200. https://doi.org/10.1136/ard.2005.038232
|
[29]
|
Li, Y., Zhu, W., Lin, R., Zhao, J. and Wang, Y. (2023) Vasoactive Intestinal Peptide Exerts Therapeutic Action by Regulating PTEN in a Model of Sjögren’s Disease. Immunity, Inflammation and Disease, 11, e936. https://doi.org/10.1002/iid3.936
|
[30]
|
Jakimovski, D., Bittner, S., Zivadinov, R., Morrow, S.A., Benedict, R.H., Zipp, F., et al. (2024) Multiple Sclerosis. The Lancet, 403, 183-202. https://doi.org/10.1016/s0140-6736(23)01473-3
|
[31]
|
Al-Keilani, M.S., Almomani, B.A., Al-Sawalha, N.A., Al Qawasmeh, M. and Jaradat, S.A. (2021) Significance of Serum VIP and PACAP in Multiple Sclerosis: An Exploratory Case-Control Study. Neurological Sciences, 43, 2621-2630. https://doi.org/10.1007/s10072-021-05682-5
|
[32]
|
Baranowska-Bik, A., Kochanowski, J., Uchman, D., Wolinska-Witort, E., Kalisz, M., Martynska, L., et al. (2013) Vasoactive Intestinal Peptide (VIP) and Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) in Humans with Multiple Sclerosis. Journal of Neuroimmunology, 263, 159-161. https://doi.org/10.1016/j.jneuroim.2013.08.012
|
[33]
|
Cobo, M., Anderson, P., Benabdellah, K., Toscano, M.G., Muñoz, P., García-Pérez, A., et al. (2013) Mesenchymal Stem Cells Expressing Vasoactive Intestinal Peptide Ameliorate Symptoms in a Model of Chronic Multiple Sclerosis. Cell Transplantation, 22, 839-854. https://doi.org/10.3727/096368912x657404
|
[34]
|
Fernandez‐Martin, A., Gonzalez‐Rey, E., Chorny, A., Ganea, D. and Delgado, M. (2006) Vasoactive Intestinal Peptide Induces Regulatory T Cells during Experimental Autoimmune Encephalomyelitis. European Journal of Immunology, 36, 318-326. https://doi.org/10.1002/eji.200535430
|
[35]
|
Rapaport, R. (2024) Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America, 53, xv-xvi. https://doi.org/10.1016/j.ecl.2023.11.002
|
[36]
|
Jimeno, R., Gomariz, R.P., Gutiérrez‐Cañas, I., Martínez, C., Juarranz, Y. and Leceta, J. (2010) New Insights into the Role of VIP on the Ratio of T‐Cell Subsets during the Development of Autoimmune Diabetes. Immunology & Cell Biology, 88, 734-745. https://doi.org/10.1038/icb.2010.29
|
[37]
|
Martin, B., Shin, Y., White, C.M., Ji, S., Kim, W., Carlson, O.D., et al. (2010) Vasoactive Intestinal Peptide–null Mice Demonstrate Enhanced Sweet Taste Preference, Dysglycemia, and Reduced Taste Bud Leptin Receptor Expression. Diabetes, 59, 1143-1152. https://doi.org/10.2337/db09-0807
|
[38]
|
Kato, I., Suzuki, Y., Akabane, A., Yonekura, H., Tanaka, O., Kondo, H., et al. (1994) Transgenic Mice Overexpressing Human Vasoactive Intestinal Peptide (VIP) Gene in Pancreatic Beta Cells. Evidence for Improved Glucose Tolerance and Enhanced Insulin Secretion by VIP and PHM-27 in Vivo. Journal of Biological Chemistry, 269, 21223-21228. https://doi.org/10.1016/s0021-9258(17)31951-8
|
[39]
|
Fanouriakis, A., Kostopoulou, M., Andersen, J., Aringer, M., Arnaud, L., Bae, S., et al. (2023) EULAR Recommendations for the Management of Systemic Lupus Erythematosus: 2023 Update. Annals of the Rheumatic Diseases, 83, 15-29. https://doi.org/10.1136/ard-2023-224762
|
[40]
|
Fu, D., Senouthai, S., Wang, J. and You, Y. (2019) Vasoactive Intestinal Peptide Ameliorates Renal Injury in a Pristane-Induced Lupus Mouse Model by Modulating Th17/Treg Balance. BMC Nephrology, 20, Article No. 350. https://doi.org/10.1186/s12882-019-1548-y
|
[41]
|
Bloom, S.R., Polak, J. and Pearse, A.G.E. (1973) Vasoactive Intestinal Peptide and Watery-Diarrhœa Syndrome. The Lancet, 302, 14-16. https://doi.org/10.1016/s0140-6736(73)91947-8
|
[42]
|
Fernandez-Montesinos, R., Castillo, P.M., Klippstein, R., Gonzalez-Rey, E., Mejias, J.A., Zaderenko, A.P., et al. (2009) Chemical Synthesis and Characterization of Silver-Protected Vasoactive Intestinal Peptide Nanoparticles. Nanomedicine, 4, 919-930. https://doi.org/10.2217/nnm.09.79
|
[43]
|
Masaka, T., Li, Y., Kawatobi, S., Koide, Y., Takami, A., Yano, K., et al. (2014) Liposome Modified with VIP-Lipopeptide as a New Drug Delivery System. Yakugaku Zasshi, 134, 987-995. https://doi.org/10.1248/yakushi.14-00019
|
[44]
|
Olson, K.E., Kosloski-Bilek, L.M., Anderson, K.M., Diggs, B.J., Clark, B.E., Gledhill, J.M., et al. (2015) Selective VIP Receptor Agonists Facilitate Immune Transformation for Dopaminergic Neuroprotection in MPTP-Intoxicated Mice. The Journal of Neuroscience, 35, 16463-16478. https://doi.org/10.1523/jneurosci.2131-15.2015
|
[45]
|
Seoane, I.V., Ortiz, A.M., Piris, L., Lamana, A., Juarranz, Y., García-Vicuña, R., et al. (2016) Clinical Relevance of VPAC1 Receptor Expression in Early Arthritis: Association with IL-6 and Disease Activity. PLOS ONE, 11, e0149141. https://doi.org/10.1371/journal.pone.0149141
|
[46]
|
Sun, W., Hong, J., Zang, Y.C.Q., Liu, X. and Zhang, J.Z. (2006) Altered Expression of Vasoactive Intestinal Peptide Receptors in T Lymphocytes and Aberrant Th1 Immunity in Multiple Sclerosis. International Immunology, 18, 1691-1700. https://doi.org/10.1093/intimm/dxl103
|